Johnson & Johnson announced a $5.5bn settlement to end long‑running U.S. litigation over its talc products. The company said it will pay up to $3bn in 2027, with the remaining amount from 2028 onward. About 76,000 claimants are expected to receive the compensation.

The resolution follows a New Jersey judge’s order requiring plaintiffs to show specific causation evidence—a demand the court said was untenable. Erik Haas, J&J’s vice‑president of litigation, said the deal lets the company put the matter behind it.

Investors have largely ignored potential liabilities; J&J shares are up 29% this year and trading at all‑time highs. Morgan Stanley analysts highlighted that the settlement could fully resolve outstanding ovarian cancer cases and remove litigation overhang.

J&J previously proposed an $8.9bn settlement in 2023 and tried a Texas‑two‑step bankruptcy scheme to ring‑fence liabilities, which courts rejected. The company maintains it has never proven its talc harmed users, citing a 2018 jury award of nearly $4.7bn to a small group of women.